Neumora Therapeutics, Inc. (NMRA)
(Delayed Data from NSDQ)
$2.63 USD
+0.32 (13.85%)
Updated Oct 24, 2025 04:00 PM ET
After-Market: $2.63 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
F Value D Growth B Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
NMRA 2.63 +0.32(13.85%)
Will NMRA be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for NMRA based on the 1-3 month trading system that more than doubles the S&P 500.

Zacks News for NMRA
JNJ Halts Development of Depression Drug Over Efficacy Concerns
Biotech Stock Roundup: NMRA Plunges on Study Failure, HOTH, VIR Soar on Study Data & More
NMRA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Neumora Stock Hits Record Low on Depression Drug Study Failure
Other News for NMRA
NMRA forms Pocket Pivot on October 24
NMRA to Host Virtual R&D Day on October 27
Neumora Therapeuticsto hold a virtual meeting
Neumora Therapeuticsto hold a virtual meeting
Crossed Above 20 Day Moving Average appears for NMRA after 35.09% move